Brokerages Expect Blueprint Medicines Corp (BPMC) Will Post Earnings of -$1.68 Per Share

Wall Street analysts expect Blueprint Medicines Corp (NASDAQ:BPMC) to announce ($1.68) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Blueprint Medicines’ earnings, with the lowest EPS estimate coming in at ($1.88) and the highest estimate coming in at ($1.30). Blueprint Medicines reported earnings per share of ($1.23) during the same quarter last year, which indicates a negative year-over-year growth rate of 36.6%. The company is scheduled to report its next earnings report on Wednesday, February 20th.

According to Zacks, analysts expect that Blueprint Medicines will report full year earnings of ($5.25) per share for the current year, with EPS estimates ranging from ($5.45) to ($4.86). For the next financial year, analysts expect that the firm will report earnings of ($7.60) per share, with EPS estimates ranging from ($9.35) to ($5.98). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Blueprint Medicines.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Tuesday, October 30th. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.09). Blueprint Medicines had a negative return on equity of 36.72% and a negative net margin of 455.15%. The company had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $1.87 million. During the same period in the prior year, the firm earned ($0.96) EPS. The firm’s revenue for the quarter was down 86.4% on a year-over-year basis.

Several analysts recently issued reports on BPMC shares. Guggenheim started coverage on shares of Blueprint Medicines in a research note on Tuesday, September 18th. They set a “buy” rating and a $102.00 price objective for the company. Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a research note on Sunday, October 7th. ValuEngine cut shares of Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 17th. BidaskClub cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Saturday, August 25th. Finally, Wedbush reissued an “outperform” rating and issued a $101.00 price target on shares of Blueprint Medicines in a research note on Monday, October 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. Blueprint Medicines presently has a consensus rating of “Buy” and an average price target of $97.14.

Shares of NASDAQ BPMC opened at $60.22 on Friday. Blueprint Medicines has a 12-month low of $57.44 and a 12-month high of $109.00. The stock has a market cap of $2.71 billion, a P/E ratio of -15.36 and a beta of 1.46. The company has a debt-to-equity ratio of 0.03, a current ratio of 10.05 and a quick ratio of 10.05.

In other news, insider Marion Dorsch sold 2,300 shares of the company’s stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $70.47, for a total value of $162,081.00. Following the transaction, the insider now directly owns 2,300 shares in the company, valued at approximately $162,081. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jeffrey W. Albers sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, November 5th. The stock was sold at an average price of $63.49, for a total transaction of $1,269,800.00. Following the completion of the transaction, the chief executive officer now owns 20,000 shares in the company, valued at $1,269,800. The disclosure for this sale can be found here. Corporate insiders own 3.15% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in BPMC. Dimensional Fund Advisors LP acquired a new stake in Blueprint Medicines during the 1st quarter worth approximately $3,940,000. Millennium Management LLC acquired a new stake in Blueprint Medicines during the 1st quarter worth approximately $5,906,000. Handelsbanken Fonder AB acquired a new stake in Blueprint Medicines during the 2nd quarter worth approximately $1,206,000. Xact Kapitalforvaltning AB lifted its holdings in Blueprint Medicines by 15.0% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 6,151 shares of the biotechnology company’s stock worth $390,000 after buying an additional 800 shares in the last quarter. Finally, Bank of Montreal Can acquired a new stake in Blueprint Medicines during the 2nd quarter worth approximately $154,000. Institutional investors own 99.73% of the company’s stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Read More: What are defining characteristics of a correction?

Get a free copy of the Zacks research report on Blueprint Medicines (BPMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply